Question explored with the scientific record
Conversation so far
- 1 Are statins worth the risk
- 2 Do statins help healthy people with high cholesterol but no disease?
Answered on this page ↓
Do statins help healthy people with high cholesterol but no disease?
For a healthy person with high cholesterol, statins do cut heart attacks and strokes. Whether they keep you alive is a smaller, shakier effect.
The strongest primary-prevention evidence here is JUPITER: rosuvastatin in healthy adults with elevated CRP cut the combined heart attack, stroke, and death endpoint, and cut all-cause deaths by 20% over a median 1.9 years [3]. In women specifically, the combined cardiovascular endpoint fell by about half [2]. But HOPE-3, in intermediate-risk adults, found no all-cause mortality difference at all over a median 5.6 years [3]. A 21-trial meta-analysis put the absolute all-cause mortality benefit at just 0.8% [3]. That is the honest size of the prize.
| Group | Outcome | Result |
|---|---|---|
| JUPITER (healthy, high CRP) | All-cause death | 20% relative cut [3] |
| HOPE-3 (intermediate risk) | All-cause death | no difference [3] |
| 21-trial meta-analysis | All-cause death | 0.8% absolute cut [3] |
| Women, primary prevention | CVD events | RR 0.63 [2] |
| Women, primary prevention | All-cause death | not significant [2] |
The cost is diabetes. A 14-trial meta-analysis found an 11% higher diabetes risk overall, rising to 18% when LDL fell hard [4]. In JUPITER, women's diabetes rate rose 49% [2]. A 2017 guideline comparison put the number needed to harm for diabetes at 38 under the 2013 rules [1].
My call: for a healthy person with high cholesterol, statins modestly reduce heart attacks and strokes, and the mortality benefit is small and inconsistent across trials. The diabetes risk is real and dose-dependent. That is a reasonable trade for someone at genuinely high risk, and a weak one for someone at low risk. Confidence: moderate.
Sources used 4
-
Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States
This study compares the eligibility for statin therapy and the estimated cardiovascular disease events prevented under the 2013 and 2016 cholesterol guidelines, highlighting the impact of the 2017 hypertension guideline on statin recommendations in the United States.
DOI: 10.1111/jch.13314 -
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia
In JUPITER, rosuvastatin reduced primary CVD events similarly in women and men with elevated hsCRP and low LDL; a meta-analysis of women in primary prevention trials found statins reduced CVD by about one-third, with a nonsignificant mortality reduction.
DOI: 10.1161/circulationaha.109.906479 -
Statin Use and the Risk of All-cause Mortality
Statins reduced all-cause mortality in some trials, but a meta-analysis found only a 0.8% absolute reduction, leaving the effect uncertain and prompting calls for trials with all-cause mortality as the primary endpoint.
DOI: 10.3904/kjm.2023.98.1.4 -
Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis
In a meta-analysis of 14 statin trials, greater LDL-c reduction was associated with increased risk of new-onset diabetes; risks were elevated with reductions of 30-50%, while reductions below 30% did not significantly increase risk.
DOI: 10.1038/srep39982